# A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care

> **NCT02279004** · — · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 840 (estimated)

## Conditions studied

- NSCLC
- Melanoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02279004
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-07-03
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 840 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02279004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02279004, "A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02279004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*